FuelCell Energy Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? FuelCell Energy Inc trades at $18 (market cap $1.47B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | SLS | |
|---|---|---|
Market Cap | $1.47B | $2.27B |
Volume | 12,559,948 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $36.01 | $15.46 |
52-Week Low | $6.00 | $1.39 |
Typical Hold Time | 48 Days | — |
Enterprise Value | $1.05B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $18.03, down 1.82% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of -$0.64, missing expectations, and has negative profitability margins. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading disclosures between June and September 2026.
The outlook remains challenging due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with a mixed rating distribution. Investment opportunities hinge on future revenue growth and cost management, while risks include ongoing litigation and failure to achieve profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →